As of 2024-12-15, the EV/EBITDA ratio of Recursion Pharmaceuticals Inc (RXRX) is -6.30. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. RXRX's latest enterprise value is 2,303.10 mil USD. RXRX's TTM EBITDA according to its financial statements is -365.32 mil USD. Dividing these 2 quantities gives us the above RXRX EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 11.4x - 15.1x | 13.8x |
| Forward P/E multiples | 13.4x - 15.3x | 15.0x |
| Fair Price | (11.55) - (13.13) | (12.51) |
| Upside | -266.1% - -288.9% | -279.9% |
| Date | EV/EBITDA |
| 2024-12-13 | -6.30 |
| 2024-12-12 | -6.34 |
| 2024-12-11 | -6.96 |
| 2024-12-10 | -6.85 |
| 2024-12-09 | -7.71 |
| 2024-12-06 | -7.43 |
| 2024-12-05 | -5.92 |
| 2024-12-04 | -6.50 |
| 2024-12-03 | -6.45 |
| 2024-12-02 | -6.97 |
| 2024-11-29 | -6.43 |
| 2024-11-27 | -5.70 |
| 2024-11-26 | -5.18 |
| 2024-11-25 | -5.29 |
| 2024-11-22 | -4.97 |
| 2024-11-21 | -5.03 |
| 2024-11-20 | -5.34 |
| 2024-11-19 | -5.58 |
| 2024-11-18 | -5.40 |
| 2024-11-15 | -5.48 |
| 2024-11-14 | -6.26 |
| 2024-11-13 | -6.70 |
| 2024-11-12 | -6.97 |
| 2024-11-11 | -7.25 |
| 2024-11-08 | -6.46 |
| 2024-11-07 | -6.28 |
| 2024-11-06 | -6.33 |
| 2024-11-05 | -6.17 |
| 2024-11-04 | -5.97 |
| 2024-11-01 | -5.72 |
| 2024-10-31 | -5.63 |
| 2024-10-30 | -6.02 |
| 2024-10-29 | -6.08 |
| 2024-10-28 | -6.22 |
| 2024-10-25 | -5.80 |
| 2024-10-24 | -5.68 |
| 2024-10-23 | -5.64 |
| 2024-10-22 | -5.94 |
| 2024-10-21 | -6.10 |
| 2024-10-18 | -6.29 |
| 2024-10-17 | -5.88 |
| 2024-10-16 | -6.37 |
| 2024-10-15 | -6.01 |
| 2024-10-14 | -6.06 |
| 2024-10-11 | -5.95 |
| 2024-10-10 | -5.48 |
| 2024-10-09 | -5.45 |
| 2024-10-08 | -5.76 |
| 2024-10-07 | -5.48 |
| 2024-10-04 | -5.41 |